Galectin Therapeutics
GALT
GALT
84 hedge funds and large institutions have $21M invested in Galectin Therapeutics in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
66% less call options, than puts
Call options by funds: $355K | Put options by funds: $1.05M
Holders
84
Holding in Top 10
–
Calls
$355K
Puts
$1.05M
Top Buyers
| 1 | +$1.58M | |
| 2 | +$384K | |
| 3 | +$366K | |
| 4 |
Millennium Management
New York
|
+$305K |
| 5 |
VCM
Vivaldi Capital Management
Chicago,
Illinois
|
+$246K |
Top Sellers
| 1 | -$1.1M | |
| 2 | -$902K | |
| 3 | -$394K | |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$287K |
| 5 |
AWS
Atria Wealth Solutions
New York
|
-$227K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AB
101
Amalgamated Bank
New York
| – |
|
|||
|
SCM
102
Sterling Capital Management
Charlotte,
North Carolina
| – |
|
|||
103
Legal & General Group
London,
United Kingdom
| – |
|